Physician profile
Stafford Smith
NPI 1710913736
$11,085.61
in general payments reported to CMS, 2019-2025
33 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $1,384 · 2021: $2,126 · 2022: $1,157 · 2023: $1,340 · 2024: $1,683 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,688 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,687.60 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,474.61 | 2019-2025 | |
| Amgen INC. | $1,356.23 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,304.27 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,236.40 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $1,000.76 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $775.34 | 2019-2025 | Brilinta, Farxiga |
| Novo Nordisk INC | $649.41 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $475.75 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian, Emblem Mri S-Icd |
| Pfizer INC. | $376.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $329.20 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.20 | 2020-2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $200.55 | 2019-2021 | |
| Amarin Pharma, INC. | $184.79 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $174.84 | 2024-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $170.85 | 2019-2024 | Evkeeza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $167.25 | 2019-2022 | |
| Medtronic, INC. | $109.34 | 2024 | Linq II |
| Scpharmaceuticals INC. | $97.35 | 2023-2025 | |
| Ekos Corporation | $93.15 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $92.10 | 2019-2021 | |
| Philips North America LLC | $79.08 | 2023 | |
| Medtronic Vascular, INC. | $78.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $70.29 | 2020-2024 | Camzyos, Eliquis |
| Biotronik INC. | $61.23 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $56.10 | 2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $40.63 | 2024-2025 | |
| Abbott Laboratories | $31.03 | 2021 | |
| Braemar Manufacturing, LLC | $25.64 | 2019 | |
| Medicomp INC | $24.78 | 2019 | |
| Irhythm Technologies, INC. | $18.51 | 2023 | Zio Xt Patch |
| Tandem Diabetes Care, INC. | $17.76 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kiniksa Pharmaceuticals International, Plc | $15.09 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stafford Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.